SAN FRANCISCO (GenomeWeb News) - Several molecular diagnostic firms are looking to unveil new assays and instrument systems that could greatly expand their market presence, company executives told investors at the JP Morgan Healthcare Conference held here this week.

Qiagen, which currently has a molecular diagnostic assay portfolio of around 120 tests, is planning to launch new instruments over the next couple of years targeting the entire molecular diagnostics market, from point of care to high-throughput labs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.